Global Group B Streptococcus (GBS) Market - 2023-2030

Overview

Group B Streptococcus (GBS) can cause potentially fatal diseases in infants within their first three months of life, including sepsis, pneumonia, and meningitis. One in four pregnant women have GBS bacteria in their bodies, which they could transmit to their unborn child during or just before birth.

There are presently no vaccines approved for prevention against group B streptococcus (GBS), although they are under development. During the first week of a newborn's life, there are measures that medical professionals can take to prevent GBS disease.

Moreover, health care professionals, pregnant women, and people in general can all benefit from a greater understanding of GBS and its potential hazards and the government taking initatives on healthcare services and technological advancements of the diseases are driving the expansion of the Group B Streptococcus market size.

Dynamics

The Rising Prevalence of Group B Streptococcus

Group B Streptococcus (GBS) is a type of bacteria that commonly resides in the human body without causing harm. GBS, however, can cause infections, particularly in infants, pregnant women, and those with weakened immune systems. GBS can pass from mother to baby after birthing and may cause serious infections in the newborn, making it an important concern in this phase of pregnancy. As such, the growth of Group B Streptococcus leads to market expansion.

For instance, according to WHO, stated that, estimated that one in five pregnant women had the bacteria Group B Streptococcus (GBS), which is a major but preventable cause of mother and newborn illness around the world. In addition, the series of 11 research articles from the London School of Hygiene & Tropical Medicine, which involved more than 100 academics from around the world, conservatively predicts that out of the 410,000 GBS cases per year, there will be at least 147,000 stillbirths and infant deaths worldwide. Africa has the biggest burden with 54% of projected cases and 65% of stillbirths and infant deaths, although having only 13% of the world's population.

Additionally, in May 2020, the first study to demonstrate the prevalence of both invasive and non-invasive Group B Streptococcus (GBS) infections among hospitalized individuals in the United States was conducted by the University of Louisville and Pfizer Inc. According to the study's authors, when both invasive and non-invasive GBS infections are taken into account, there are 188,570 GBS-related hospitalizations and 5,660 deaths among U.S. individuals 18 and older every year. Thus, all of these factors boost market expansion.

The Rising the Clinical Trials on Group B Streptococcus

The rising clinical trials for developing and launching several new drugs are drive the market growth. For instance, on September 07, 2022, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved the breakthrough therapy designation to its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, for the purpose of preventing invasive GBS disease caused by vaccine serotypes in newborns and young infants through active immunization of their mothers during pregnancy.

Moreover, in April 2023, to evaluate the safety and immunogenicity of its novel GBS vaccine in the older adult population with Group B Streptococcus (GBS), MinervaX has initiated a Phase I clinical trial. In the trial, conducted at the Centre for Vaccinology (CEVAC) in Ghent, Belgium, older persons aged 55 to 75 with and without underlying medical issues would get two doses of the GBS vaccination. Due to an insufficient immunological response, older persons with comorbidities will receive three doses of the GBS vaccination. Therefore, increased rising the clinical trials for developing novel drugs for better treatment and prevention are anticipated to create market growth.

Side Effects Associated with the Treatment

GBS colonization typically has no symptoms or side effects. GBS can, however, infect individuals in need, which can result in a number of health issues and difficulties. GBS infections can cause pneumonia, a serious occasionally fatal disease that affects the entire body, particularly in infants and people with compromised immune systems. Additionally, GBS infections in pregnant women are less frequent but can result in postpartum infections, chorioamnionitis, and urinary tract infections. Thus, all of the above reasons restrict market growth.

Segment Analysis

The global Group B Streptococcus(GBS) market is segmented based on infection type, treatment, end user and region.

Antibiotics are Only needed for Treat Bacterial Infections

During the delivery process, medical professionals treat patients with intravenous (IV) antibiotics to avoid GBS infection in the baby. Penicillin or ampicillin is the most often used antibiotic to treat group B strep. Antibiotic administration to the patient at this time helps prevent the transmission of GBS from mother to newborn. GBS treatment prior to delivery is effective. It is preferable to take the antibiotics at least four hours before birth. This kind of therapy prevents about 90% of infections. Therefore, the segment's expansion is accelerated by the usage of antibiotics.

Moreover, according to NLM, stated that, the preferred method of treatment for intrapartum antibiotic prophylaxis against Group B Streptococcus is intravenous penicillin G. A loading dose of 5 million units of penicillin G is given intravenously, and then 2.5 to 3 million units are given every four hours throughout delivery process. If penicillin G is not available, ampicillin is a suitable substitute. During labor and up until delivery, ampicillin is given as a 2 gm intravenous loading dose followed by 1 gm intravenous every 4 hours. Thus, all of these factors boost segment expansion.

Geographical Penetration

Expanding the Health Services in the Region

North America was the most significant market for GBS. The market has grown as a consequence of North America's expanding need for healthcare services. In addition, the region's growth is contributed to by factors like rising pregnancy rates, rising health expenditures, and increasing product launches and product approvals.

For instance, in November 2022, a molecular diagnostic test for the qualitative detection of Group B Streptococcus (GBS) using enriched Lim broth cultures of patient samples has been made public by Cepheid. It is called Xpert GBS LB XC (extended coverage). The success of the 2012 release of Xpert GBS LB is built upon by Xpert GBS LB XC. The next-generation test is already available, and US customers will start receiving shipments in November. Preventing newborn GBS infections depends on accurate antepartum GBS testing. To enhance performance and coverage, Xpert GBS LB XC includes new dual targets in highly conserved GBS genomic regions. Thus, all of these factors will be contributing in boosting regional growth.

COVID-19 Impact Analysis

The effect of COVID-19 on the treatment of GBS may not be directly related, however there may be some potential indirect effects. For instance, many healthcare systems became overloaded with the care of COVID-19 patients at the peak of the COVID-19 pandemic. The management and treatment of other diseases, including GBS infections, may be impacted by this strain on resources and medical staff. In an effort to stop the spread of GBS to newborns following childbirth, pregnant women are frequently checked for colonization.

However, COVID-19-related complications in prenatal care could impact the early detection and treatment of GBS colonization in pregnant women. Moreover, the increased use of antibiotics to treat severe COVID-19 cases may indirectly affect the treatment of GBS infections through supporting the growth of antibiotic-resistant bacteria.

By Infection Type

• Bacteremia
• Meningitis
• Sepsis
• Pneumonia
• Bone and joint infections
• Skin and soft tissue infections
• Urinary tract infections

By Treatment

• Antibiotics
• Surgery

By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In December 2022, according to a Hong Kong study, prenatal screening significantly lowers baby infections and mortality from common bacterial infections. Around 20% of expecting moms carry the Group B Streptococcus bacteria, which is mostly harmless but can have negative effects on babies. After universal screening was implemented, the number of babies with the infection decreased from one in 1,000 to 0.2 in 1,000.
• On September 28, 2022, the development and accessibility of maternal vaccines against Group B Streptococcus (GBS) and Respiratory Syncytial Virus (RSV), two of the leading causes of infant and newborn mortality in low-income countries, will be supported by grants from the Bill & Melinda Gates Foundation totaling nearly $128 million.
• In December 2022, A 72 million EUR financing round for MinervaXApS, a privately held Danish biotechnology company researching a new vaccine against Group B Streptococcus (GBS), has been successfully completed. In addition to existing investors REPAIR Impact Fund (Novo Holdings), Sunstone Life Science Ventures, LF Investment, Wellington Partners, Sanofi Ventures, Adjuvant Capital, and Industrifonden, the 22-million-euro equity financing was co-led by new investors Trill Impact Ventures and PureosBioventures.

Competitive Landscape

The major global players in the market include Pfizer Inc, MinervaXApS, Wellstat Vaccines LLC, GlaxoSmithKline, LUMINEX CORPORATION, PATH, USAntibiotics, Novartis, HAL, TAJ LIFE SCIENCES PVT. LTD and among others.

Why Purchase the Report?

• To visualize the global Group B Streptococcus (GBS) market segmentation based on infection type, treatment, end user and region as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Group B Streptococcus (GBS) market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global Group B Streptococcus (GBS) market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies